Zastosowanie praktyczne duloksetyny w terapii depresji i lęku. Najczęściej pojawiające się pytania i wątpliwości Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
cze 30, 2018
Słowa kluczowe:
duloksetyna, depresja, zaburzenie lękowe uogólnione, ból, SNRI
##plugins.themes.bootstrap3.article.main##
Abstrakt
W ostatnich latach ukazało się wiele publikacji porównujących duloksetynę z innymi lekami przeciwdepresyjnymi. Dodatkowo rosnąca liczba doświadczeń ze stosowaniem duloksetyny w różnych populacjach pozwala na wyciągnięcie wniosków oraz zarówno usytuowanie jej wśród pozostałych leków przeciwdepresyjnych, jak i wyodrębnienie grup pacjentów, którzy mogą w szczególności odnieść korzyści z leczenia nią. W artykule podsumowano obecny stan wiedzy na temat praktycznego zastosowania duloksetyny w terapii depresji i lęku, odnosząc się do najczęściej pojawiających się pytań i wątpliwości.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Antosik-Wójcińska, A. (2018). Zastosowanie praktyczne duloksetyny w terapii depresji i lęku. Najczęściej pojawiające się pytania i wątpliwości . Medycyna Faktów , 11(2(39), 112-117. https://doi.org/10.24292/01.MF.0218.2
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Eckert L., Lancon C.: Duloxetine compared with fluoxetine and venlafaxine: use of meta-regression analysis for indirect comparisons. BMC Psychiatry 2006; 6: 30.
2. Schueler Y.B., Koesters M., Wieseler B. et al.: A systematic review of duloxetine and venlafaxine in major depression, including unpublished data. Acta Psychiatr. Scand. 2011; 123: 247-265.
3. Papakostas G.I., Thase M.E., Fava M. et al.: Are Antidepressant Drugs That Combine Serotonergic and Noradrenergic Mechanisms of Action More Effective Than the Selective Serotonin Reuptake Inhibitors in Treating Major Depressive Disorder? A Meta-analysis of Studies of Newer Agents. Biol. Psychiatry 2007; 62: 1217-1227.
4. Arnold L.M., Lu Y., Crofford L.J. et al.: A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum. 2004; 50: 2974-2984.
5. Arnold L.M., Rosen A., Pritchett Y.L. et al.: A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 2005; 119: 5-15.
6. Perahia D.G., Quail D., Desaiah D. et al.: Switching to duloxetine in selective serotonin reuptake inhibitor non- and partial-responders: effects on painful physical symptoms of depression. J. Psychiatr. Res. 2009a; 43: 512-518.
7. Raskin J., Wiltse C.G., Siegal A. et al.: Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am. J. Psychiatry 2007; 164: 900-909.
8. Romera I., Pérez V., Menchón J.M. et al.: Early vs. conventional switching of antidepressants in patients with MDD and moderate to severe pain: a double-blind randomized study. J. Affect. Disord. 2012; 143: 47-55.
9. Papakostas G.I., Fava M., Thase M.E. et al.: Treatment of SSRI-Resistant Depression: A Meta-analysis Comparing Within-Versus Across-Class Switches. Biol. Psychiatry 2008; 63: 699-674.
10. Karp J.F., Whyte E.M., Lenze E.J. et al.: Rescue Pharmacotherapy with Duloxetine for SSRI Nonresponders in Late Life Depression: Outcome and Tolerability. J. Clin. Psychiatry 2008; 69: 457-463.
11. Perahia D.G., Gilaberte I., Wang F. et al.: Duloxetine in the prevention of relapse of major depressive disorder: double-blind placebo-controlled study. Br. J. Psychiatry 2006b; 188: 346-353.
12. Perahia D.G., Maina G., Thase M.E. et al.: Duloxetine in the prevention of depressive recurrences: a randomized, double-blind, placebo controlled trial. J. Clin. Psychiatry 2009b; 70: 706-716.
13. Nelson J.C., Wohlreich M.M., Mallinckrodt C.H. et al.: Duloxetine for the treatment of major depressive disorder in older patients. Am. J. Geriatr. Psychiatry 2005; 13: 227-235.
14. Derby M.A., Zhang L., Chappell J.C. et al.: The effects of supratherapeutic doses of duloxetine on blood pressure and pulse rate. J. Cardiovasc. Pharmacol. 2007; 49: 384-393.
15. Ball S.G., Desaiah D., Zhang Q. et al.: Efficacy and safety of duloxetine 60 mg once daily in major depressive disorder: a review with expert commentary. Drugs Context 2013a; 2013: 212245.
16. Ball S., De Berardis D., Serroni N. et al.: The role of duloxetine in the treatment of anxiety disorders. Neuropsychiatr. Dis. Treat 2008; 4: 929-935.
17. Hartford J., Kornstein S., Liebowitz M. et al.: Duloxetine as an SNRI treat-ment for generalized anxiety disorder: results from a placebo and active- controlled trial. Int. Clin. Psychopharmacol. 2007; 22: 167-174.
18. Nierenberg A.A., Greist J.H., Mallinckrodt C.H. et al.: Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study. Curr. Med. Res. Opin. 2007; 23: 401-416.
19. Shelton R.C., Prakash A., Mallinckrodt C.H. et al.: Patterns of depressive symptom response in duloxetine-treated outpatients with mild, moderate or more severe depression. Int. J. Clin. Pract. 2007; 61: 1337-1348.
2. Schueler Y.B., Koesters M., Wieseler B. et al.: A systematic review of duloxetine and venlafaxine in major depression, including unpublished data. Acta Psychiatr. Scand. 2011; 123: 247-265.
3. Papakostas G.I., Thase M.E., Fava M. et al.: Are Antidepressant Drugs That Combine Serotonergic and Noradrenergic Mechanisms of Action More Effective Than the Selective Serotonin Reuptake Inhibitors in Treating Major Depressive Disorder? A Meta-analysis of Studies of Newer Agents. Biol. Psychiatry 2007; 62: 1217-1227.
4. Arnold L.M., Lu Y., Crofford L.J. et al.: A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum. 2004; 50: 2974-2984.
5. Arnold L.M., Rosen A., Pritchett Y.L. et al.: A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 2005; 119: 5-15.
6. Perahia D.G., Quail D., Desaiah D. et al.: Switching to duloxetine in selective serotonin reuptake inhibitor non- and partial-responders: effects on painful physical symptoms of depression. J. Psychiatr. Res. 2009a; 43: 512-518.
7. Raskin J., Wiltse C.G., Siegal A. et al.: Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am. J. Psychiatry 2007; 164: 900-909.
8. Romera I., Pérez V., Menchón J.M. et al.: Early vs. conventional switching of antidepressants in patients with MDD and moderate to severe pain: a double-blind randomized study. J. Affect. Disord. 2012; 143: 47-55.
9. Papakostas G.I., Fava M., Thase M.E. et al.: Treatment of SSRI-Resistant Depression: A Meta-analysis Comparing Within-Versus Across-Class Switches. Biol. Psychiatry 2008; 63: 699-674.
10. Karp J.F., Whyte E.M., Lenze E.J. et al.: Rescue Pharmacotherapy with Duloxetine for SSRI Nonresponders in Late Life Depression: Outcome and Tolerability. J. Clin. Psychiatry 2008; 69: 457-463.
11. Perahia D.G., Gilaberte I., Wang F. et al.: Duloxetine in the prevention of relapse of major depressive disorder: double-blind placebo-controlled study. Br. J. Psychiatry 2006b; 188: 346-353.
12. Perahia D.G., Maina G., Thase M.E. et al.: Duloxetine in the prevention of depressive recurrences: a randomized, double-blind, placebo controlled trial. J. Clin. Psychiatry 2009b; 70: 706-716.
13. Nelson J.C., Wohlreich M.M., Mallinckrodt C.H. et al.: Duloxetine for the treatment of major depressive disorder in older patients. Am. J. Geriatr. Psychiatry 2005; 13: 227-235.
14. Derby M.A., Zhang L., Chappell J.C. et al.: The effects of supratherapeutic doses of duloxetine on blood pressure and pulse rate. J. Cardiovasc. Pharmacol. 2007; 49: 384-393.
15. Ball S.G., Desaiah D., Zhang Q. et al.: Efficacy and safety of duloxetine 60 mg once daily in major depressive disorder: a review with expert commentary. Drugs Context 2013a; 2013: 212245.
16. Ball S., De Berardis D., Serroni N. et al.: The role of duloxetine in the treatment of anxiety disorders. Neuropsychiatr. Dis. Treat 2008; 4: 929-935.
17. Hartford J., Kornstein S., Liebowitz M. et al.: Duloxetine as an SNRI treat-ment for generalized anxiety disorder: results from a placebo and active- controlled trial. Int. Clin. Psychopharmacol. 2007; 22: 167-174.
18. Nierenberg A.A., Greist J.H., Mallinckrodt C.H. et al.: Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study. Curr. Med. Res. Opin. 2007; 23: 401-416.
19. Shelton R.C., Prakash A., Mallinckrodt C.H. et al.: Patterns of depressive symptom response in duloxetine-treated outpatients with mild, moderate or more severe depression. Int. J. Clin. Pract. 2007; 61: 1337-1348.